What's actually happening at Week 5
The shift from Phase 1 to Phase 2 isn't additive — it's compounded. MOTS-c is encoded in mitochondrial DNA and activates AMPK, the cellular energy sensor. In a primed mitochondrion, AMPK activation signals biogenesis, fat oxidation, and glucose disposal. In an unprimed one it triggers an oxidative burst that depletes the very ATP you're trying to build. That's why the practitioner corpus is uniform on sequencing: Phase 1 stabilizes, Phase 2 pushes. Skip the prep and you compound the deficit.
5-Amino-1MQ runs parallel as the NAD+ amplifier. NNMT (nicotinamide N-methyltransferase) is the enzyme that consumes methyl donors and degrades NAM, the recyclable precursor in the NAD+ salvage pathway. Blocking NNMT does two things at once: it preserves NAD+ pool size by stopping the leak, and it frees methyl groups for downstream methylation reactions (SAMe, homocysteine clearance, neurotransmitter synthesis). Practitioners running NAD+ optimization protocols consistently pair NNMT inhibition with mitochondrial biogenesis — the math is simple: more NAD+ in a mitochondrion that can actually use it. The 5-Amino-1MQ literature also describes parallel lipolysis effects via blocking the obesity-associated NNMT pathway, which is why fasted morning dosing stacks well with the MOTS-c metabolic window.
The nightly GH pulse — CJC-1295 with Ipamorelin — closes the loop. CJC-1295 DAC provides the sustained GHRH baseline at 2 mg once weekly (8+ day half-life, dose timing flexible). Ipamorelin provides the clean, sharp pulse with no cortisol or prolactin spillover. The corpus is consistent: dose Ipamorelin before bed on an empty stomach, 2+ hours after the last meal. The synthetic pulse stacks with the natural slow-wave sleep GH surge, and the result is elevated overnight IGF-1, accelerated tissue repair, and the metabolic environment for simultaneous fat loss and muscle preservation — exactly what the Week 5-10 window needs to convert mitochondrial repair into systemic recomposition.
BPC-157 enters here as the opportunistic add-on. Once the ATP surplus is real, BPC-157 leverages it for systemic tissue repair — gut lining, tendon, vascular endothelium. The practitioner pattern is unambiguous: BPC-157 works harder in a high-ATP environment than a depleted one. Week 5+ is when adding it pays compounding returns.
The Weeks 5-10 stack
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| MOTS-c | 5 mg (titrate to 10 mg) | SubQ | Mon/Thu | Expert | Start at 5 mg twice weekly. If tolerated, increase to 10 mg by Week 7. Activates AMPK; encoded in mitochondrial DNA. Total 10–20 mg/week across the stack. |
| 5-Amino-1MQ | 50–100 mg | Oral | Daily | Expert | Morning, ideally fasted. Blocks NNMT to preserve NAD+ pool size. Stacks well with a fasted training window. |
| CJC-1295 (DAC) | 2 mg | SubQ | 1x/week | Expert | Any day, any time — 8+ day half-life makes timing flexible. Provides sustained GHRH baseline. |
| Ipamorelin | 100–200 mcg | SubQ | Nightly | Expert | Before bed, empty stomach (2+ hours after last meal). Stacks with natural slow-wave sleep GH pulse. Cleanest secretagogue — no cortisol/prolactin spillover. |
| BPC-157 | 500 mcg – 1 mg | SubQ | Daily | Expert | Add from Week 5 to leverage the ATP surplus for systemic tissue repair (gut, tendon, vascular). |
| Methylene Blue (carry-over from Phase 1) | 0.5–1 mg | Oral | Daily | Experimental | Continue from prep phase. Electron-transport-chain stabilizer; hormetic — keep dose low. |
What you should feel
Week-by-week pattern drawn from the practitioner corpus:
- Week 5–6: Morning energy is the first marker. The pattern reported is a clear lift in the first hour after waking — not stimulant-like, but absence of the "wading through molasses" baseline. Sleep architecture starts shifting: deeper slow-wave sleep, fewer 3 AM wake-ups. This is the GH pulse loading and the NAD+ pool stabilizing.
- Week 7–8: Body composition starts to visibly shift. Stubborn fat depots (lower abdomen, flanks) recede as the 5-Amino-1MQ + MOTS-c combination drives lipolysis and fat oxidation. Strength output holds or rises despite ongoing fat loss — that's the IGF-1 signature from the nightly GH pulse.
- Week 9–10: Cognitive endurance extends. The late-afternoon crash flattens. The mitochondrial biogenesis from MOTS-c is now producing functional new mitochondria — you're operating on a larger energy ledger, not just a topped-up tank.
What's NOT happening yet
- You're not regenerating telomeres. That's the Epitalon layer — typically a separate 10–20 day burst, 2–3 times per year. Cellular energy and cellular longevity are adjacent, not identical. Don't conflate them.
- The GH pulse is not anabolic in the testosterone sense. Expect lean-mass preservation and modest gain — not pharmacological hypertrophy. The point of the pulse is recovery and IGF-1, not muscle-stack performance.
- NAD+ is not at "20-year-old peak." It's meaningfully higher than your Phase 1 baseline, but the lift is logarithmic, not linear. Practitioners running NAD+ panels see directional improvement during active 5-Amino-1MQ + MOTS-c phases, not a return to pediatric levels.
- The protocol is not hardened for indefinite use. Phase 2 is a 6-week active window. By Week 10 you're prepping the off-cycle or maintenance transition — running MOTS-c past 8 weeks shows diminishing returns in the corpus, and the standard pattern is 4–8 weeks on, 4 weeks off.
- If fatigue worsens in the first 1–2 weeks of MOTS-c, that's not the protocol working — that's the oxidative-burst signal that prep was insufficient. Stop MOTS-c, extend the preparatory phase, retest. The corpus is explicit: this is data, not failure.
Research describes this trajectory. Track energy, sleep, and recovery metrics daily — the data validates the protocol, or it doesn't, and the next move depends on which.